B-cell lymphoma refractory

10 trials 4 recruiting MedDRA PT
10 Registered trials
4 Recruiting
7 Unique sponsors
14 Unique IMPs
9 Commercial trials
Drug classes (ATC)
— ATC code not specified 8
H Endocrinology (ATC H) 1
L Oncology (ATC L) 2
Mechanism of action (INN-stem analysis)
IMiD 2 substances
Unknown / small molecule 2 substances
CAR-T cell therapy 1 substance
Monoclonal antibody 1 substance
Alkylating agent 1 substance
Anthracycline 1 substance
BTK inhibitor 1 substance
Antibody-drug conjugate (ADC) 1 substance
Corticosteroid 1 substance
Monoclonal antibody (chimeric) 1 substance
BCL-2 inhibitor 1 substance
Monoclonal antibody (rat) 1 substance
Phase II: 4 Phase I/II: 2 Phase I: 3 Phase I (First in Human): 1

Filter these 10 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 10 trials

Phase II

4 trials
  • Miltenyi Biomedicine GmbH Commercial
    ZAMTOCABTAGENE AUTOLEUCEL
    2023-506270-13-00 15 countries 2021 n=223 Orphan
    Ended
  • Miltenyi Biomedicine GmbH Commercial
    ZAMTOCABTAGENE AUTOLEUCEL
    2023-506348-17-00 4 countries 2025 n=12 Orphan
    Recruiting
  • Miltenyi Biomedicine GmbH Commercial
    ZAMTOCABTAGENE AUTOLEUCEL
    2023-508508-39-01 2 countries n=4
    Pending
  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR Academic
    TAFASITAMAB
    2024-514775-17-00 1 country 2021 n=64
    Ended

Phase I/II

2 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    CYCLOPHOSPHAMIDE; DOXORUBICIN HYDROCHLORIDE; EPCORITAMAB; GOLCADOMIDE; IBRUTINIB; LENALIDOMIDE; POLATUZUMAB VEDOTIN; PREDNISOLONE; RITUXIMAB; VENETOCLAX
    2023-505347-38-00 7 countries 2022 n=59 Orphan
    Recruiting
  • Miltenyi Biomedicine GmbH Commercial
    AUTOLOGOUS T-CELLS TRANSDUCED WITH LENTIVIRAL VECTOR EXPRESSING A CHIMERIC ANTIGEN RECEPTOR DIRECTED AGAINST CD19; MB-CART20.1; ZAMTOCABTAGENE AUTOLEUCEL
    2022-501648-14-00 1 country 2024 n=40 Orphan
    Recruiting

Phase I

3 trials
  • Immunome Inc. Commercial
    IMP not specified
    2025-523160-20-00 4 countries 2026 n=41
    Recruiting
  • Kite Pharma Inc. Commercial
    IMP not specified
    2024-511616-24-00 2 countries 2024 n=25
    Ended
  • Ubix Therapeutics Inc. Commercial
    IMP not specified
    2023-510484-35-00 1 country n=42
    Pending

Phase I (First in Human)

1 trial
  • Genmab A/S Commercial
    EPCORITAMAB
    2023-504802-12-00 9 countries 2018 n=395 Orphan
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Miltenyi Biomedicine GmbH Commercial 4 Phase II, Phase I/II 2
Immunome Inc. Commercial 1 Phase I 1
Kite Pharma Inc. Commercial 1 Phase I 0
Ubix Therapeutics Inc. Commercial 1 Phase I 0
Genmab A/S Commercial 1 Phase I (First in Human) 0
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase I/II 1
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR Academic 1 Phase II 0
New trials by year
2021
2
2022
1
2024
2
2025
1
2026
1
← All indication landscapes